modelJ05AP03
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Boceprevir | |
| ATC code: | J05AP03 | route: | oral |
| compartments: | 1 | |
| dosage: | 800 | mg |
| volume of distribution: | 193 | L |
| clearance: | 16.4 | L/hr |
| other parameters in model implementation | ||
Boceprevir is a direct-acting antiviral drug that inhibits the NS3/4A serine protease of hepatitis C virus (HCV). It was used in combination with other antiviral drugs (such as peginterferon alfa and ribavirin) for the treatment of chronic HCV infection, specifically genotype 1. Boceprevir was approved by the FDA in 2011 but has been discontinued and is no longer marketed due to newer, more effective HCV medications with better safety profiles.
Pharmacokinetics
Pharmacokinetics reported for healthy adult subjects (both sexes), after multiple oral doses of 800 mg three times daily.
References
Westberg, M, et al., & Lin, MZ (2024). An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations. Science translational medicine 16(738) eadi0979–None. DOI:10.1126/scitranslmed.adi0979 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38478629
Gentile, I, et al., & Borgia, G (2014). Dasabuvir: A Non-Nucleoside Inhibitor of NS5B for the Treatment of Hepatitis C Virus Infection. Reviews on recent clinical trials 9(2) 115–123. DOI:10.2174/1574887109666140529222602 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24882169
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)